The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.
 
David Starks
No Relationships to Disclose
 
Luis Alexander Rojas-Espaillat
No Relationships to Disclose
 
Nandini Dey
No Relationships to Disclose
 
Pradip De
Consulting or Advisory Role - Viecure
 
Brian Leyland-Jones
Leadership - NED Biosystems
Stock and Other Ownership Interests - ARIAD; Catalyst Pharmaceuticals; Progenix; Puma Biotechnology; Sucampo Pharmaceuticals; Zogenix
Consulting or Advisory Role - Amgen; GlaxoSmithKline
Speakers' Bureau - Bayer; Exelixis; Genentech; Puma Biotechnology
Research Funding - Takeda; Tesaro
Expert Testimony - Amgen
Travel, Accommodations, Expenses - AKESOgen; National Foundation for Cancer Research
Other Relationship - AKesoGen; OTraces; SciTech Development LLC
 
Casey B. Williams
Employment - Genentech/Roche (I); Macrogenics (I)
Consulting or Advisory Role - Astellas Pharma; Takeda; VieCure
Research Funding - Kiadis Pharma (Inst); Takeda (Inst); Tesaro (Inst)
Travel, Accommodations, Expenses - Takeda (Inst)